Hyperpolarised xenon magnetic resonance spectroscopy for the longitudinal assessment of changes in gas diffusion in IPF
Open Access
Abstract
Prognosticating idiopathic pulmonary fibrosis (IPF) is challenging, in part due to a lack of sensitive biomarkers. A recent article inThoraxdescribed how hyperpolarised xenon magnetic resonance spectroscopy may quantify regional gas exchange in IPF lungs. In a population of patients with IPF, we find that the xenon signal from red blood cells diminishes relative to the tissue/plasma signal over a 12-month time period, even when the diffusion factor for carbon monoxide is static over the same time period. We conclude that hyperpolarised129Xe MR spectroscopy may be sensitive to short-term changes in interstitial gas diffusion in IPF.Keywords
Funding Information
- National Institute for Health and Care Research
This publication has 9 references indexed in Scilit:
- Using hyperpolarized 129Xe MRI to quantify regional gas transfer in idiopathic pulmonary fibrosisThorax, 2017
- Effect of continued treatment with pirfenidone following clinically meaningful declines in forced vital capacity: analysis of data from three phase 3 trials in patients with idiopathic pulmonary fibrosisThorax, 2016
- Assessment of lung function in asthma and COPD using hyperpolarized 129Xe chemical shift saturation recovery spectroscopy and dissolved‐phase MRINMR in Biomedicine, 2014
- Experimental validation of the hyperpolarized 129Xe chemical shift saturation recovery technique in healthy volunteers and subjects with interstitial lung diseaseMagnetic Resonance in Medicine, 2014
- Efficacy and Safety of Nintedanib in Idiopathic Pulmonary FibrosisNew England Journal of Medicine, 2014
- Regional mapping of gas uptake by blood and tissue in the human lung using hyperpolarized xenon‐129 MRIJournal of Magnetic Resonance Imaging, 2013
- Pirfenidone in patients with idiopathic pulmonary fibrosis (CAPACITY): two randomised trialsThe Lancet, 2011
- Functional lung imaging using hyperpolarized gas MRIJournal of Magnetic Resonance Imaging, 2007
- Analyses of Efficacy End Points in a Controlled Trial of Interferon-γ1b for Idiopathic Pulmonary FibrosisChest, 2005